Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice
Sam D. Molyneux, … , Lawrence S. Kirschner, Rama Khokha
Sam D. Molyneux, … , Lawrence S. Kirschner, Rama Khokha
Published August 9, 2010
Citation Information: J Clin Invest. 2010;120(9):3310-3325. https://doi.org/10.1172/JCI42391.
View: Text | PDF
Research Article Oncology Article has an altmetric score of 15

Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice

  • Text
  • PDF
Abstract

Some cancers have been stratified into subclasses based on their unique involvement of specific signaling pathways. The mapping of human cancer genomes is revealing a vast number of somatic alterations; however, the identification of clinically relevant molecular tumor subclasses and their respective driver genes presents challenges. This information is key to developing more targeted and personalized cancer therapies. Here, we generate a new mouse model of genomically unstable osteosarcoma (OSA) that phenocopies the human disease. Integrative oncogenomics pinpointed cAMP-dependent protein kinase type I, α regulatory subunit (Prkar1a) gene deletions at 11qE1 as a recurrent genetic trait for a molecularly distinct subclass of mouse OSA featuring RANKL overexpression. Using mouse genetics, we established that Prkar1a is a bone tumor suppressor gene capable of directing subclass development and driving RANKL overexpression during OSA tumorigenesis. Finally, we uncovered evidence for a PRKAR1A-low subset of human OSA with distinct clinical behavior. Thus, tumor subclasses develop in mice and can potentially provide information toward the molecular stratification of human cancers.

Authors

Sam D. Molyneux, Marco A. Di Grappa, Alexander G. Beristain, Trevor D. McKee, Daniel H. Wai, Jana Paderova, Meenakshi Kashyap, Pingzhao Hu, Tamara Maiuri, Swami R. Narala, Vuk Stambolic, Jeremy Squire, Josef Penninger, Otto Sanchez, Timothy J. Triche, Geoffrey A. Wood, Lawrence S. Kirschner, Rama Khokha

×

Total citations by year

Year: 2024 2023 2022 2021 2020 2019 2018 2016 2015 2014 2013 2012 2011 2010 2009 Total
Citations: 3 2 1 4 3 2 3 9 4 12 4 5 3 1 1 57
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article in year 2013 (4)

Title and authors Publication Year
Localized interleukin-12 delivery for immunotherapy of solid tumours
LZ Wei, Y Xu, ME Nelles, C Furlonger, JC Wang, MA di Grappa, R Khokha, JA Medin, CJ Paige
Journal of Cellular and Molecular Medicine 2013
Genome-wide association study identifies two susceptibility loci for osteosarcoma
SA Savage, L Mirabello, Z Wang, JM Gastier-Foster, R Gorlick, C Khanna, AM Flanagan, R Tirabosco, IL Andrulis, JS Wunder, N Gokgoz, A Patiño-Garcia, L Sierrasesúmaga, F Lecanda, N Kurucu, IE Ilhan, N Sari, M Serra, C Hattinger, P Picci, LG Spector, DA Barkauskas, N Marina, SR de Toledo, AS Petrilli, MF Amary, D Halai, DM Thomas, C Douglass, PS Meltzer, K Jacobs, CC Chung, SI Berndt, MP Purdue, NE Caporaso, M Tucker, N Rothman, MT Landi, DT Silverman, P Kraft, DJ Hunter, N Malats, M Kogevinas, S Wacholder, R Troisi, L Helman, JF Fraumeni, M Yeager, RN Hoover, SJ Chanock
Nature Genetics 2013
cAMP/PKA signaling defects in tumors: genetics and tissue-specific pluripotential cell-derived lesions in human and mouse
CA Stratakis
Molecular and Cellular Endocrinology 2013
Phylooncogenomics: Examining the cancer genome in the context of vertebrate evolution
GJ Zhang, TH Vemulapalli, JY Yang
Applied & Translational Genomics 2013

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Blogged by 1
Referenced in 3 patents
On 1 Facebook pages
56 readers on Mendeley
1 readers on CiteULike
See more details